TOKYO -- Chemical and materials group AGC has started producing an additive for a coronavirus vaccine candidate being developed by U.S. company Novavax, the Japanese manufacturer said Thursday.
U.S. subsidiary AGC Biologics has been contracted to produce an adjuvant, a compound that improves a vaccine's effectiveness. The agent is being manufactured at a plant in Denmark.
